(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 December 2011 (15.12.2011)

PCT

(10) International Publication Number
WO 2011/156518 A2

(51) International Patent Classification:
C07D 405/12 (2006.01) *A61K 31/352* (2006.01)
C07D 405/10 (2006.01) *A61P 35/00* (2006.01)
C07D 311/04 (2006.01) *A61P 25/28* (2006.01)
A61K 31/453 (2006.01)

(21) International Application Number:
PCT/US2011/039669

(22) International Filing Date:
8 June 2011 (08.06.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/353,531 10 June 2010 (10.06.2010) US

(71) Applicant *(for all designated States except US)*: **ARAGON PHARMACEUTICALS, INC.** [—/US]; 12780 El Camino Real, Suite #301, San Diego, CA 92130 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **KAHRAMAN, Mehmet** [TR/US]; 8617 Via Mallorca Unit E, La Jolla, CA 92037 (US). **GOVEK, Steven, P.** [US/US]; 13216 Via Santillana, San Diego, CA 92129 (US). **NAGASAWA, Johnny, Y.** [JP/US]; 8525 Park Run Road, San Diego, CA 92129 (US). **SMITH, Nicholas, D.** [US/US]; 1204 Beryl Street, San Diego, CA 92109 (US).

(74) Agents: **HOSTETLER, Michael, J.** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2011/156518 A2

(54) **Title**: ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

(57) **Abstract**: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.